Brief Summary
This is a first in human study of a new potential treatment drug HH3806 for patients with relapsed/refractory NHL or advancedat a late stage, far along solid tumors. This study aims to determine the maximum safest dosethe amount of medication taken of HH3806 that may be administered to cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs patients as a single therapy. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and to determine maximum safest dose of HH3806 that will be administered orally as a single therapy in adult patients with advanced malignancies.
Intervention/Treatment
- Drug: HH3806.
Inclusion Criteria
- Male and female patients 18years of age or older.
- Provide informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. voluntarily prior to initiation of any study-related procedures.
- Tumor type criteria: Histologically or cytologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of one of the following advanced malignancy:
- Solid tumors that meet the following criteria:
- Measurable disease by RECIST v1.1 in at least 1 site with the exception of Castration-Resistant Prostatea walnut-shaped gland in the male reproductive system that is responsible for producing semen - a bodily fluid that acts as a vessel for sperm transport during ejaculation Cancer (CRPC), who may be enrolled with objective evidence of disease as per certain criteria; disease progression with the last line of therapy and at least one prior standard of care regimens, or for which there is no approved therapy, or for which standard therapy is unsuitable or refused. Patients must have disease not amenable to surgerytreatment involving removal of cancerous tissue and/or tumours and a margin of healthy tissue around it to reduce recurrence, radiation, or combined modality therapy with curative intent. Patients without treatment options available known to provide clinical benefit are also eligible
- Relapsed/refractory NHL must have received at least 2 prior systemic therapies and there is no standard salvage regimen available.
- Solid tumors that meet the following criteria:
- Life expectancy greater than or equal to 3 months.
- ECOG performance status less than or equal to 1.
- Patient must have adequate organ function measured within 28 days of screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening.